Cleo Diagnostics Ltd (COV) — Strategic Asset Allocation Index

Latest as of December 2025: 0.3%

Cleo Diagnostics Ltd (COV) has a Strategic Asset Allocation Index of 0.3% as of December 2025. Strategic assets (PP&E of AU$27.73K plus long-term investments of AU$-) total AU$27.73K, measured against net assets of AU$8.83 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See how leveraged is Cleo Diagnostics Ltd's balance sheet to measure how much of total assets are equity-financed.

SAAI

0.3%
Strategic Assets / Net Assets

Strategic Assets

AU$27.73K
PP&E + LT Investments

PP&E

AU$27.73K
AUD

Net Assets

AU$8.83 Million
AUD

Cleo Diagnostics Ltd Strategic Asset Allocation Index (2024–2025)

This chart shows how Cleo Diagnostics Ltd's Strategic Asset Allocation Index has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the index stands at 0.3%, representing strategic assets of AU$27.73K against net assets of AU$8.83 Million AUD. For live market cap and overall valuation, see how much is Cleo Diagnostics Ltd worth.

Annual Strategic Asset Allocation Index for Cleo Diagnostics Ltd (2024–2025)

The table below presents the year-by-year Strategic Asset Allocation Index for Cleo Diagnostics Ltd from 2024 to 2025, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See shareholders equity of Cleo Diagnostics Ltd for net asset value and shareholders' equity analysis.

Year SAAI Strategic Assets (AUD) PP&E LT Investments Net Assets Change (pp)
2025 0.6% AU$32.59K AU$32.59K AU$- AU$5.83 Million ▲ +0.2 pp
2024 0.3% AU$31.95K AU$31.95K AU$- AU$9.39 Million
pp = percentage points